Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,378.90up ₹20.90 (1.54%)BSE ₹1,380.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,358.00.
30 Oct: open ₹1,362.00, high ₹1,381.70, low ₹1,357.00
52-week range of traded prices to 30 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,11,397 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.45
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.15
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,36,66155.4% delivered
Cipla orders, deals and press releases
311 filed, newest first. Page 7 of 7.
Apr 2013
Feb 2013
28 Feb · Business
Nov 2012
Jul 2012
May 2012
Aug 2010
May 2010
7 May · Business
Board of Directors of the Company at its meeting held on May 07, 2010 have inter alia approved the acquisition of two manufacturing facilities which hitherto were manufacturing formulations and bulk drugs/ intermediates exclusively for the Company for an aggregate consideration of Rs. 82.02 crores as follows: (i) Acquisition of a Company for Rs. 51.38 crores, which has a state of the art formulations manufacturing facility at Sikkim with capabilities to manufacture Tablets, Capsules, Oral liquids, Injections, Liquid and Ointments/ Creams. The Company is eligible for a 10 year tax holiday under the Income Tax Act, 1961 commencing from the financial year 2009-10. (ii) Acquisition of undertaking for Rs. 30.64 crores, by way of slump sale arrangement. The undertaking is located at Kurkumbh (District Pune) and has US FDA & WHO approved manufacturing facility for bulk drugs / intermediates. These acquisitions are being done with an objective to exercise control over operations of these facilities. Entities controlled by relatives of the promoters are major shareholders in the Company / facilities proposed to be acquired. The aggregate consideration for both acquisitions was determined on the basis of valuation reports provided by Grant Thornton and fairness opinions provided by Kotak Mahindra Capital Company Limited.
Mar 2010
23 Mar · Business
Cipla Ltd. has informed the Exchange regarding a press release dated March 23, 2010, titled "Piramal Healthcare Limited Acquires "i-pill", India's No 1 Emergency Contraceptive Brand from Cipla Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2009
29 Sep · Business
Cipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 29, 2009 , at Hyderabad has issued and allotted 2,56,30,000 fully paid-up equity Shares of Rs. 2 each ("Equity Share") at an issue price of Rs.263.75 per Equity Share (including a premium of Rs.261.75 per Equity Share) aggregating to Rs.6,75,99,12,500 to qualified institutional bidders by way of a qualified institutions placement in terms of Chapter VIII of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009".25 Sep · Business
Cipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 24, 2009 has decided to close the bid period and has approved issuance of 2,56,30,000 Equity Shares of Rs. 2 each of the Company at a price of Rs. 263.75 per Equity Share (including a premium of Rs. 261.75 per equity share) under the QIP issue, aggregating to Rs. 6,75,99,12,500/-. The Committee has also approved the Placement Document in respect of the Equity Shares proposed to be issued as aforesaid."